Skip to content
Screener

CG Oncology CGON Q1 2026 earnings

Reported May 8, 2026 · Before market open

Revenue$1.1MBeat by $630.0K
EPS-$0.71Miss by $0.13
Revenue estimate$453.0K
EPS estimate-$0.58

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$547.7K
EPS estimate-$0.86

Financials

Q1 2026

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$5.71B+206%
Enterprise value$5.69B+212%
P/S1,126.9×-1,693×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0×0.0×
Current ratio31.3×+0.3×

Segments

By product

See full
Commercial And Development Revenue$1.1M—
License And Collaboration Revenue$14.0K-73.1%

FAQ

When did CG Oncology report Q1 2026 earnings?
CG Oncology (CGON) reported Q1 2026 earnings on May 8, 2026 before market open.
What were CG Oncology's Q1 2026 revenue and EPS?
CG Oncology reported revenue of $1.1M and eps of $-0.71 for Q1 2026.
Did CG Oncology beat estimates in Q1 2026?
Revenue beat the consensus estimate of $453.0K by $630.0K. EPS missed the consensus estimate of $-0.58 by $0.13.
How did CG Oncology's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1982.7% from $52.0K a year earlier and eps declined 57.8% from $-0.45.
Where can I find CG Oncology's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-213440) and the 10-Q periodic report (0001193125-26-214669) directly on SEC EDGAR. The filing index links above go to sec.gov.